Register Login

uniQure NV (QURE)

(90% Positive) uniQure NV (QURE) Announces Enrollment Update for option Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 6:30 p.m.

    📋 uniQure NV (QURE) - Clinical Trial Update

    Filing Date: 2026-01-13

    Accepted: 2026-01-13 07:05:15

    Event Type: Clinical Trial Update

    Event Details:

    uniQure NV (QURE) Announces Clinical Trial Update uniQure NV (QURE) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: option, pathway
    • Diseases/Conditions: AMT-130
    • Collaboration: Huntington

    🔬 Clinical Development Pipeline (uniQure NV):

    Product Type Development Stage Therapeutic Area Source
    rAAV2/5-PBGD vector dosage 4 GENETIC Phase PHASE1 Acute Intermittent Porphyria ClinicalTrials.gov
    rAAV2/5-PBGD vector dosage 3 GENETIC Phase PHASE1 Acute Intermittent Porphyria ClinicalTrials.gov
    rAAV2/5-PBGD vector dosage 2 GENETIC Phase PHASE1 Acute Intermittent Porphyria ClinicalTrials.gov
    rAAV2/5-PBGD vector dosage 1 GENETIC Phase PHASE1 Acute Intermittent Porphyria ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: uniQure NV
    • Ticker Symbol: QURE

Search

News categories